• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Bladder Cancer Drug Pipeline Update 2014 Product Image

Bladder Cancer Drug Pipeline Update 2014

  • Published: March 2014
  • Region: Global
  • Bioseeker

According to the American Cancer Society, bladder cancer is the 6th most common cancer in the U.S. Bladder cancer occurs among both men and women. When found and treated early, the 5 year survival rate is 94%.
There are today 102 companies plus partners developing 121 drugs targeting bladder cancer in development. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 31 drugs. Bladder Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 106 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 103 out of the 104 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 41 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

How May Drug Pipeline Update Be READ MORE >

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos